ArticleJAMA2024
Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant?
Article in JAMA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06811324 (The Effects of Tirzepatide Use on Muscle and Vascular Function Among Obese Older Adults), which is not on this map. Cited by 97 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Tirzepatide Use on Muscle and Vascular Function Among Obese Older Adults
Who cites it
97 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Lipedema: Progress, Challenges, and the Road Ahead.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Pooled it
- The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review.Journal of cachexia, sarcopenia and muscle · 2025Pooled it
- GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials.Obesity (Silver Spring, Md.) · 2025Pooled it
- Diet-based weight-loss intervention is not associated with a meaningful change in lean soft tissue.The American journal of clinical nutrition · 2026Trial
- Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.Diabetes, obesity & metabolism · 2025Trial
- Characterization of the effect of naltrexone/bupropion on body composition.Diabetes, obesity & metabolism · 2025Trial
- Comparative Efficacy of GLP-1 Receptor Agonists, Exercise, and Their Combination on Body Composition and Glucolipid Metabolism in Adults With Overweight or Obesity: A Network Meta-Analysis of Randomized Controlled Trials.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Review
- Update on clinical heart failure trials.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Review
- Preoperative Weight Loss: Helpful, Harmful or Irrelevant?Obesity surgery · 2026Article
- A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications.Obesity science & practice · 2026Review
- Defining Healthy Weight Loss and Target Weight in the Era of Highly Effective Treatment of Patients With Obesity.Journal of cachexia, sarcopenia and muscle · 2026Review
- Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Article
- Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study.The Lancet regional health. Europe · 2026Article
- Response to "Standardizing Obesity Imaging: From Confirmation of Excess Adiposity to Integrated Body Composition Phenotyping".Korean journal of radiology · 2026Article
- The evolving landscape of obesity pharmacotherapy.Nature reviews. Drug discovery · 2026Review
- Article
- 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- SEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials.Diabetes, obesity & metabolism · 2026Observational
- Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Association between estimated glucose disposal rate and sarcopenia in U.S. adults: a cross-sectional study based on NHANES 2011-2018.Diabetology & metabolic syndrome · 2026Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
38829659What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.